Actieve functies van Scott Bratman
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
Adela, Inc.
 Adela, Inc. Finance/Rental/LeasingFinance Adela, Inc. is a company that is developing technology to accelerate the diagnosis and improve the management of cancer through blood tests for minimal residual disease (MRD) monitoring and multi-cancer early detection (MCED). The company is based in Branford, CT. The company's genome-wide methylome enrichment platform captures extensive, biologically-relevant genomic information to maximize test performance and improve treatment decisions. Adela's approach to MRD testing is tissue agnostic, eliminating the burden of acquiring a tumor sample. The CEO of the company is Scott Bratman. | Corporate Officer/Principal | - | - |
| Directeur/Bestuurslid | - | - | |
| Algemeen Directeur | - | 25-09-2023 | |
| President | - | - |
Loopbaan van Scott Bratman
Statistieken
Internationaal
| Verenigde Staten | 2 |
Operationeel
| Director/Board Member | 1 |
| Chief Executive Officer | 1 |
| Corporate Officer/Principal | 1 |
Sectoraal
| Finance | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Bedrijven in privébezit | 1 |
|---|---|
Adela, Inc.
Adela, Inc. Finance/Rental/LeasingFinance Adela, Inc. is a company that is developing technology to accelerate the diagnosis and improve the management of cancer through blood tests for minimal residual disease (MRD) monitoring and multi-cancer early detection (MCED). The company is based in Branford, CT. The company's genome-wide methylome enrichment platform captures extensive, biologically-relevant genomic information to maximize test performance and improve treatment decisions. Adela's approach to MRD testing is tissue agnostic, eliminating the burden of acquiring a tumor sample. The CEO of the company is Scott Bratman. | Finance |
- Beurs
- Insiders
- Scott Bratman
- Ervaring
